PA
ALAB icon

PharVision Advisers’s Astera Labs ALAB Stock Holding History

PharVision Advisers’s Portfolio ALAB Stock Details ALAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,154
Closed -$358K – 670
2025
Q4 		$358K Buy
+2,154
New +$360K 0.18% 175
2025
Q1 		– Sell
-2,758
Closed -$365K – 541
2024
Q4 		$365K Buy
+2,758
New +$259K 0.31% 97

Other funds holding ALAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AM
Atreides Management Boston, Massachusetts $14.3B AUM 116.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

PharVision Advisers's ALAB Position: Q1 2026 in Review

PharVision Advisers sold out of Astera Labs (ALAB) in Q1 2026, closing a stake of 2,154 shares — an estimated $358K sold.

PharVision Advisers first reported a position in ALAB in Q4 2024 and held it in 2 quarters. The position peaked at $365K in Q4 2024. 708 funds tracked by Wall St. Rank hold ALAB as of Q1 2026.

  • PharVision Advisers reported no remaining Astera Labs position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 2,154 Astera Labs shares in Q1 2026, an estimated $358K.
  • PharVision Advisers first reported a position in Astera Labs in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Astera Labs position peaked at $365K in Q4 2024.
  • 708 funds tracked by Wall St. Rank held Astera Labs as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.